# Angelman Syndrome FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/angelman-syndrome

> 4 upcoming FDA catalysts in Angelman Syndrome: obudanersen (IONS) on August 2027 (primary completion); obudanersen (IONS) on Aug to Nov 2027 (topline data readout); obudanersen (IONS) on May 2028 (primary completion); obudanersen (IONS) on May to Aug 2028 (topline data readout).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| July 10, 2026 | [Apazunersen primary completion](https://sec-api.dev/pdufa/apazunersen) | RARE | Angelman Syndrome | withdrawn | "NCT06617429 (Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2026-07-10 (ACTUAL); Lead Sponsor Ultragenyx Pharmaceutical Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06617429)) |
| October 30, 2026 | [Apazunersen primary completion](https://sec-api.dev/pdufa/apazunersen) | RARE | Angelman Syndrome | withdrawn | "NCT06415344 (Long-term Extension of GTX-102 in Angelman Syndrome): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2026-10-30 (ACTUAL); Lead Sponsor Ultragenyx Pharmaceutical Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06415344)) |
| October 30, 2026 | [Apazunersen primary completion](https://sec-api.dev/pdufa/apazunersen) | RARE | Angelman Syndrome | withdrawn | "NCT07157254 (A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-10-30 (ACTUAL); Lead Sponsor Ultragenyx Pharmaceutical Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07157254)) |
| August 2027 | [Obudanersen primary completion](https://sec-api.dev/pdufa/obudanersen) | IONS | Angelman Syndrome | scheduled | "NCT06914609 (REVEAL: A Phase 3 Study of Obudanersen (ION582) in Angelman Syndrome): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Ionis Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06914609)) |
| Aug to Nov 2027 | [Obudanersen topline data readout](https://sec-api.dev/pdufa/obudanersen) | IONS | Angelman Syndrome | scheduled | "NCT06914609 (REVEAL: A Phase 3 Study of Obudanersen (ION582) in Angelman Syndrome): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Ionis Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06914609)) |
| May 2028 | [Obudanersen primary completion](https://sec-api.dev/pdufa/obudanersen) | IONS | Angelman Syndrome | scheduled | "NCT07782827 (CHAMPION: A Study to Evaluate the Efficacy and Safety of Obudanersen (ION582) in Children and Adults With Angelman Syndrome (AS)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05 (ESTIMATED); Lead Sponsor Ionis Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07782827)) |
| May to Aug 2028 | [Obudanersen topline data readout](https://sec-api.dev/pdufa/obudanersen) | IONS | Angelman Syndrome | scheduled | "NCT07782827 (CHAMPION: A Study to Evaluate the Efficacy and Safety of Obudanersen (ION582) in Children and Adults With Angelman Syndrome (AS)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05 (ESTIMATED); Lead Sponsor Ionis Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07782827)) |

## Drugs

- [Apazunersen](https://sec-api.dev/pdufa/apazunersen) (RARE)
- [Obudanersen](https://sec-api.dev/pdufa/obudanersen) (IONS)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/angelman-syndrome.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Angelman Syndrome FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/angelman-syndrome

```bibtex
@misc{secapidev_indications_angelman_syndrome_20261116,
  title        = {Angelman Syndrome FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/angelman-syndrome}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_angelman_syndrome_20261116","title":"Angelman Syndrome FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/angelman-syndrome","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
